Chlvpp is as Effective as Alternating ChlvppAbod in Advanced Stage Hodgkin's Disease

References

• Urba W. J., Longo D. L. Medical progress: Hodgkin's disease. New Engl J Med 1992; 326: 678–87
   PubMed Web of Science ®Google Scholar
• DeVita V. T., Jr., Hubbard S. M. Hodgkin's disease. N Engl J Med 1993; 328: 560–5
   PubMed Web of Science ®Google Scholar
• Longo D. L. The use of chemotherapy in the treatment of Hodgkin's disease. Semin Oncol 1990; 17: 716–35
   PubMed Web of Science ®Google Scholar
• Bartlett N. L., Rosenberg S. A., Hoppe R. T., Hancock S. L., Horning S. J. Brief chemotherapy, Stanford V. and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J Clin Oncol 1995; 13: 1080–8
   PubMed Web of Science ®Google Scholar
• van Leeuwen F. E., Jokman W. J., Hagenbeek A. Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 1994; 12: 312–25
   PubMed Web of Science ®Google Scholar
• Abrahamsen J. F., Andersen A., Hannisdal E. Second malignancies after treatment of Hodgkin's disease: The influence of treatment, follow-up time, and age. J Clin Oncol 1993; 11: 255–61
   PubMed Web of Science ®Google Scholar
• Lund M. B., Kongerud J., Nome O. Lung function impairment in long-term survivors of Hodgkin's disease. Ann Oncol 1995; 6: 495–501
   PubMed Web of Science ®Google Scholar
• Cooper J. A. D., Jr., White D. A., Matthay R. A. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 1986; 133: 321–40
   PubMed Web of Science ®Google Scholar
• Kantrowitz N. E., Bristow M. R. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis 1984; 27: 195–200
   PubMed Web of Science ®Google Scholar
• Bauer K. A., Skarin A. T., Balikian J. Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am J Med 1993; 74: 557–63
   Google Scholar
• Minow R. A., Benjamin R. S., Lee E. T., Gottlieb J. A. Adriamycin cardiomyopathy—risk factors. Cancer 1977; 39: 1397–402
   PubMed Web of Science ®Google Scholar
• DeVita V. T., Jr. Is alternating cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease?. No. Important Adv Oncol 1993; 197–208
   Google Scholar
• Dady P. J., Mc EIwain T. J., Austin D. E., Barrett A., Peckham M. J. Five years' experience with ChlVPP: Effective low-toxicity combination chemotherapy for Hodgkin's disease. Br J Cancer 1982; 45: 851–9
   PubMed Web of Science ®Google Scholar
• Santoro A., Bonadonna G., Bonfante V., Valagussa P. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 1982; 306: 770–5
   PubMed Web of Science ®Google Scholar
• DeVita V. T., Jr., Serpick A. A., Carbone P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970; 73: 881–95
   PubMed Web of Science ®Google Scholar
• Lukes R. J., Craver L. F., Hall T. C. Report of the nomenclature committee. Cancer Res 1966; 26: 1311
   Web of Science ®Google Scholar
• McElwain T. J., Toy J., Smith E. A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Br J Cancer 1977; 3: 7–10
   Google Scholar
• Bonadonna G., Zucali R., Monfardini S., DeLena M., Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxam-ide versus MOPP. Cancer 1975; 36: 252–9
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Hagemeister F. B., McLaughlin P. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407–12
   PubMed Web of Science ®Google Scholar
• Santoro A., Viviani S., Valagussa P., Bonfante V., Bonadonna G. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol 1986; 13: 23–6
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81
   Web of Science ®Google Scholar
• Peto R., Pike M. C., Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Dixon W. J., Brown M. B., Engelman L., Jennrich R. I. BMDP Statistical Software Manual. 1990
   Google Scholar
• Longo D. L., Duffey P. L., DeVita V. T., Jr., Wesley M. N., Hubbard S. M., Young R. C. The calculation of actual or received dose intensity: A comparison of published methods. J Clin Oncol 1991; 9: 2042–51
   PubMed Web of Science ®Google Scholar
• Connors J. M. Is cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease?. Yes. Important Adv Oncol 1993; 95–189
   Google Scholar
• Longo D. L., Duffey P. L., DeVita V. T., Jr. Treatment of advanced-stage Hodgkin's disease: Alternating noncrossresis-tant MOPP/CABS is not superior to MOPP. J Clin Oncol 1991; 9: 1409–20
   PubMed Web of Science ®Google Scholar
• Canellos G. P., Anderson J. R., Propert K. J. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–84
   PubMed Web of Science ®Google Scholar
• Somers R., Carde P., Henry Amar M. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12: 279–87
   PubMed Web of Science ®Google Scholar
• Radford J. A., Crowther D., Rohatiner A. Z. S., Ryder W. D. J., Gupta R. K., Oza A. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 1995; 13: 2379–85
   PubMed Web of Science ®Google Scholar
• Druker B. J., Rosenthal D. S., Canellos G. P. Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease. Cancer 1989; 63: 1060–4
   PubMed Web of Science ®Google Scholar
• Gomez G. A., Panahon A. M., Stutzman L. Large mediastinal mass in Hodgkin's disease. Results of two treatment modalities. Am J Clin Oncol 1984; 7: 65–73
   PubMed Web of Science ®Google Scholar
• Crnkovich M. J., Leopold K., Hoppe R. T., Mauch P. M. Stage I to IIB Hodgkin's disease: The combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol 1987; 5: 1041–9
   PubMed Web of Science ®Google Scholar
• Mauch P., Gorshein D., Cunningham J. Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease. Cancer Treat Rep 1982; 66: 809–17
   PubMedGoogle Scholar
• Pavlovsky S., Maschio M., Santarelli M. T. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst 1988; 80: 1466–73
   PubMed Web of Science ®Google Scholar
• Longo D. L., Russo A., Duffey P. L. Treatment of advanced-stage massive mediastinal Hodgkin's disease: The case for combined modality treatment. J Clin Oncol 1991; 9: 227–35
   PubMed Web of Science ®Google Scholar
• Austin-Seymour M. M., Hoppe R. T., Cox R. S., Rosenberg S. A., Kaplan H. S. Hodgkin's disease in patients over sixty years old. Ann Intern Med 1984; 100: 13–8
   PubMed Web of Science ®Google Scholar
• Specht L., Nissen N. I. Hodgkin's disease and age. Eur J Haematol 1989; 43: 127–35
   PubMed Web of Science ®Google Scholar
• Eghbali H., Hoerni Simon G., de Mascarel I., Durand M., Chauvergne J., Hoerni B. Hodgkin's disease in the elderly. A series of 30 patients aged older than 70 years. Cancer 1984; 53: 2191–3
   PubMed Web of Science ®Google Scholar
• Walker A., Schoenfeld E. R., Lowman J. T., Mettlin C. J., MacMillan J., Grufferman S. Survival of the older patient compared with the younger patient with Hodgkin's disease. Influence of histologic type, staging, and treatment. Cancer 1990; 65: 1635–40
   PubMed Web of Science ®Google Scholar
• Erdkamp F. L., Breed W. P., Bosch L. J., Wijnen J. T., Blijham G. B. Hodgkin's disease in the elderly. A registry-based analysis. Cancer 1992; 70: 830–4
   PubMed Web of Science ®Google Scholar
• Enblad G., Glimelius B., Sundström C. Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. Ann Oncol 1991; 2: 297–302
   PubMed Web of Science ®Google Scholar
• Peterson B. A., Pajak T. F., Cooper M. R. Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep 1982; 66: 889–98
   PubMedGoogle Scholar
• van Leeuwen F. E., Chorus AM, Van den Belt J, Dusebout A. W. Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994; 12: 1063–73
   PubMed Web of Science ®Google Scholar
• Viviani S., Ragni G., Santoro A. Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer 1991; 27: 1389–92
   PubMed Web of Science ®Google Scholar
• Clark S. T., Radford J. A., Crowther D., Swindell R., Shalet S. M. Gonadal function following chemotherapy for Hodgkin's disease: A comparative study of MVPP and a seven-drug hybrid regimen. J Clin Oncol 1995; 13: 134–9
   PubMed Web of Science ®Google Scholar